Keyphrases
Antiangiogenic Agents
25%
Combination Strategy
100%
Combination Therapy
25%
Expanded Indication
100%
Immunotherapeutics
25%
Inhibitor Combination
25%
Novel Combinations
100%
Ovarian Cancer
100%
PARP Inhibitor (PARPi)
100%
PARP Inhibitor Resistance
25%
Poly (ADP-ribose) Polymerase Inhibition
25%
Therapeutic Indications
25%
Transforming Care
25%
U.S. Food
25%
Medicine and Dentistry
Angiogenesis Inhibitor
20%
Combination Therapy
20%
Immunomodulating Agent
20%
Ovarian Cancer
100%
PARP Inhibitor
100%
Poly ADP Ribose Polymerase
20%
Pharmacology, Toxicology and Pharmaceutical Science
Angiogenesis Inhibitor
20%
Combination Therapy
20%
Immunomodulating Agent
20%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
20%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Ovary Cancer
100%